This approval adds to Granules India's existing 67 ANDA approvals from the US FDA, strengthening its position in regulated ...

Alembic Pharmaceuticals receives USFDA approval for its generic Diltiazem Hydrochloride extended-release capsules used to ...

Alembic Pharmaceuticals Ltd on Monday said it has received final approval from the US health regulator for its generic ...

Granules India announced today that the U.S. Food & Drug Administration (USFDA) has approved the Abbreviated New Drug Application (ANDA) for Bupropion Hydrochloride Extended-Release Tablets USP (SR) ...

Bupropion hydrochloride extended-release tablets are widely prescribed for the treatment of major depressive disorder and for ...

Granules India has received USFDA approval to market a generic medication for major depressive disorder, Bupropion ...

Diltiazem Hydrochloride Extended-Release Capsules USP, 120 mg, 180 mg, and 240 mg have an estimated market size of US$ 28.2 ...

Diltiazem Hydrochloride is prescribed to treat hypertension (high blood pressure) and chronic stable angina (chest pain).

The abbreviated new drug application (ANDA) for the product was filed with the USFDA by Granules Pharmaceuticals, Inc. (GPI), ...

Granules Pharmaceuticals, Inc., a 100% foreign subsidiary of Granules India received the U.S. Food & Drug Administration (USFDA) approval for abbreviated new drug application (ANDA) of Bupropion ...

A driver and passenger were arrested early Thursday morning after an officer located boxes of Promethazine Hyrdochloride and ...

The company has received approval for its Abbreviated New Drug Application for Bupropion Hydrochloride extended-release ...